Article
Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.
Molecular cancer therapeutics - 1 Nov 2020
Pucciarelli Daniela, Angus Steven P, Huang Benjamin, Zhang Chi, Nakaoka Hiroki J, Krishnamurthi Ganesh, Bandyopadhyay Sourav, Clapp D Wade, Shannon Kevin, Johnson Gary L, Nakamura Jean L
Abstract excerpt
Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of drug resistance and ultimately disease progression. To investigate molecular signatures in the context of NF1 loss and subsequent acquired drug resistance, we analyzed the exomes,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.